GlaxoSmithKline has licensed exclusive world-wide rights to EUSA Pharma, Inc.’s preclinical human anti-interleukin-6 antibody for a consideration of as much as $44 million, which includes an upfront fee, development milestones and royalties on future sales. As part of the agreement, EUSA will pay approximately half of this total amount to its development partner, Vaccinex, Inc. GSK will be responsible for all future development, production and commercialization of the product.     Inter...